Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Take Our Regulators—Please!

David S. Pisetsky, MD, PhD  |  Issue: February 2009  |  February 1, 2009

In a spirit of patriotism … I have a modest proposal: I think that we should give the regulators watching over medicine (and that means you and me) over to the Treasury to watch over the financial system.

Where will these regulators come from? Regulators don’t grow on trees and finding good ones may be no mean feat. I worry that we may not have enough regulators around to keep the financial big boys on the straight and narrow.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a spirit of patriotism to help our country reform, I have a modest proposal: I think that we should give the regulators watching over medicine (and that means you and me) over to the Treasury to watch over the financial system.

In the past decade, medicine has been different than other parts of the economy. Whereas deregulation fever took over the banks, in medicine, it was just the opposite as regulation fever sent our temperatures soaring. There are now rules governing just about everything. Soon, I am sure that we have a rule specifying the number of bathroom breaks a house office needs in 24 hours.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Consider a piece of news I heard on “The Rachel Maddow Show” on MSNBC. According to Maddow, the form required for a bank to get money from the Troubled Asset Relief Program (TARP) is just two pages long. Perhaps Maddow was exaggerating (she is on MSNBC after all) and other forms are needed. If the claim about the form is true, all I can say is “yikes” and I am going to put whatever money I have left under the mattress. It seems safer under there if that is how TARP will work.

I was struck by this story because, in my realm, regulations and red tape have proliferated like kudzu. Indeed, virtually everything I do has been subjected to increasing regulatory oversight and requires voluminous documentation with forms that are chock full of complex, confusing, and redundant questions. A recent protocol I submitted to use 200 mice was almost 50 pages long, and a request to collect a few more de-identified sera took two months of review and another gargantuan form.

CME is a thicket of regulation and miles of red tape. For every lecture I deliver, I complete a disclosure form that seems to ask about everything including the contents of my kids’ piggy banks. My PowerPoint presentation is then uploaded for the eyes of some grand inquisitor who will search for bias or recommendations of drugs for unapproved indications. (As you know, important parts of rheumatology therapy involve the off-label use of drugs. We are in a quandary here.)

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Legislation & AdvocacyOpinionRheuminationsSpeak Out Rheum Tagged with:Healthcare ReformPoliticsRegulation

Related Articles

    Exploring the Complement System in Human Disease

    February 1, 2010

    Novel disease associations revealed by whole genome screens

    Is It Time to Replace the HAQ?

    July 12, 2011

    The PROMIS initiative uses item response theory to improve assessment of patient-reported health and wellbeing

    Drug Updates: Information on New Approvals and Medication Safety

    January 1, 2010

    Information on New Approvals and Medication Safety

    Drug Updates

    September 1, 2009

    Information on New Approvals and Medication Safety

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences